03-08-07

Express Mail Label No.: EV 978771837 US
Date of Deposit: March 6, 2007

Attorney Docket No.: 24492-011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Brand *et al.*		
SERIAL NUMBER:	10/691,123	EXAMINER:	Marcela M. Cordero Garcia
FILING DATE:	October 22, 2003	ART UNIT:	1654
FOR:	TREATMENT OF DIABETES		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (7 pages), in duplicate;
3. Copies of Cited References: B5-B16; C15-C121;
4. Check in the amount of $180.00 (#23750); and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24492-011. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 6, 2007

Express Mail Label No. EV 978771837 US
Date of Deposit: March 6, 2007

Attorney Docket No.: 24492-011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand *et al.*
SERIAL NUMBER: 10/691,123 EXAMINER: Marcela M. Cordero Garcia
FILING DATE: October 22, 2003 ART UNIT: 1654
FOR: TREATMENT OF DIABETES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of $180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A12-A15 and U.S. Published Applications A16-A26 are not submitted. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24492-011.

Respectfully submitted,

03/09/2007 CNGUYEN2 00000078 10691123
01 FC:1806 180.00 OP

Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 6, 2007

Express Mail No.: EV 978771837 US
Date of Deposit: March 6, 2007

Please type a plus sign (+) in this box [+]

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/691,123
Filing Date	October 22, 2003
First Named Inventor	Brand
Group Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	24492-011

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A12	6,899,883 B2	05/31/05	Dupre	424	198.1	
	*A13	6,989,148 B2	01/24/06	Dupre	424	198.1	
	*A14	6,992,060 B2	01/31/06	Brand	514	2	
	*A15	7,037,504 B2	05/02/06	Magil et al.	424	198.1	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A16	2002/0081285	06/27/02	Parikh et al.	424	93.21	
	*A17	2002/0119146 A1	08/29/02	Dupre	424	139.1	
	*A18	2004/0023885 A1	02/05/04	Brand et al.	514	12	
	*A19	2004/0037818 A1	02/26/04	Brand et al.	424	93.21	
	*A20	2004/0209801 A1	10/21/04	Brand et al.	514	12	
	*A21	2004/0209816 A1	10/21/04	Parikh et al.	514	12	
	*A22	2004/0229810 A1	11/18/04	Cruz	514	14	
	*A23	2004/0266682 A1	12/30/04	Cruz	514	12	
	*A24	2006/0183674 A1	08/17/06	Brand et al.	514	11	
	*A25	2006/0234373 A1	10/19/06	Rabinovitch et al.	435	325	
	*A26	2006/0234932 A1	10/19/06	Brand	514	12	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B5	CA	2 494 134	WARATAH PHARMACEUTICALS, INC.	12/04/03		
	B6	CA	2 486 584	WARATAH PHARMACEUTICALS, INC.	12/18/03		
	B7	WO	95/19785	RESEARCH TRIANGLE PHARMACEUTICALS LTD.	07/27/95		
	B8	WO	00/044400	RTP PHARMA INC.; THE GENERAL HOSPITAL CORPORATION	08/03/00		
	B9	WO	03/100024 A2	WARATAH PHARMACEUTICALS, INC.; UNIVERSITY OF ALBERTA	12/04/03		
	B10	WO	03/103701 A1	WARATAH PHARMACEUTICALS, INC.	12/18/03		

	B11	WO	2004/037195 A2	WARATAH PHARMACEUTICALS, INC.	05/06/04		
	B12	WO	2004/045640 A1	WARATAH PHARMACEUTICALS, INC.	06/03/04		
	B13	WO	2004/096853 A1	WARATAH PHARMACEUTICALS, INC.	11/11/04		
	B14	WO	2004/105780 A2	WARATAH PHARMACEUTICALS, INC.	12/0904		
	B15	WO	2005/072045 A2	WARATAH PHARMACEUTICALS, INC.	08//11/05		
	B16	WO	2006/002532 A1	WARATAH PHARMACEUTICALS, INC.	01/12/06		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	**Cite No.**	**Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.**
	C15	Adams et al., "Insulin-like growth factor-I promotes successful fetal pancreas transplantation in the intramuscular site", *Surgery*, 116:751-757 (1994)
	C16	Andrews et al., "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas", *J. Biol. Chem.*, 260:3910-3914 (1985)
	C17	Baggio et al., "Sustained expression of exendin-4 does not perturb glucose homeostais, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice", *J. Biol. Chem.*, 275:34472-34477 (2000)
	C18	Brelje et al., "The physiological roles of prolactin, growth hormone and placental lactogen in the regulation of islet β cell proliferation", *Pancreatic Growth and Regeneration*, Ed. N. Sarvetnick, Ch. 1, pgs. 1-30 (1997)
	C19	Carpenter et al., in Peptide Growth Factors, Chapter 4, "The Epidermal Growth Factor Family", eds. Sporn and Roberts, Springer Verlag, pgs. 69-171 (1990)
	C20	Chedid et al., "Regulation of Keratinocyte Growth Factor Gene Expression by Interleukin 1", *J Biol. Chem.*, 269(14):10753-10757 (1994)
	C21	Cunningham et al., "Receptor and antibody Epitopes in human growth hormone identified by homolog-scanning mutagenesis", *Science*, 243:1330-1336 (1989)
	C22	Cunningham, et al., "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis", *Science*, 244:1081-1085 (1989)
	C23	D'Alessio, et al., "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal", *J. Clin. Invest.*, 93:2263-2266 (1994)
	C24	Dockray et al., "Immunochemical Characterization of Gastrin in Pancreatic Islets of Normal and Genetically Obese Mice", *J. Endocrinol.*, 72: pp 143-151 (1977)
	C25	Dupre, et al., "Insulinotropic Effect of Glucagon-Like Peptide I (7-36) Amide in C-Peptide-Positive Type I Diabetes Mellitus," *Clin. Invest. Med.*, **Abstract 221**, Page B38 (1994)
	C26	Durrant et al, "Co-stimulation of Gastrointestinal Tumour Cell Growth by Gastrin, Transforming Growth Factor α and Insulin Like Growth Factor-1", *Br. J. Cancer*, 63:67-70 (1991)
	C27	Edwards et al., "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers", *Am. J. Physiol. Endocrinol. Metab.* 281:E155-E161 (2001)
	C28	Egan et al., "Glucagon-like Peptide-1 (7-36) Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extrapancreatic Sites of GLP-1 Action", *Endocrinol.*, 135(5):2070-2075 (1994)
	C29	Fehmann et al., "Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells", *Endocrinol.*, 130(1):159-66 (1992)
	C30	Ghiglione et al., "How Glucagon-Like is Glucagon-Like peptide?", *Diabetologia*, 27:599-600 (1984)
	C31	Gil et al., "Polymeric Biomaterials as drug delivery systems", *Boletim de Biotecnologia*, 72:13-19 (2002)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C32	Goeddel et al., "Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone", *Nature*, 281:544-548 (1979)
	C33	Goke et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-Amide an Antagonist at the Glucagon-Like Peptide 1-(7-36)-Amide Receptor of Insulin-Secreting Beta-Cells", *J. Biol. Chem.*, 268:19650-19655 (1993)
	C34	Gray et al., "Periplasmic production of correctlyu processed human growth hormone in Escherichia coli: natural and bacterial signal sequences are interchangeable", *Gene*, 39:247-254 (1985)
	C35	Gromada et al., "Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1", *Eur. J. Physiol.*, 435:583-94 (1998)
	C36	Gromada et al., "Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting .beta.TC3 Cells: Role of PKA-independent Mechanisms ", *Brit. J. Pharmacol.*, 118:769-775 (1996)
	C37	Gromada et al., "Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic .beta.-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling", *Diabetes*, 47:57-65 (1998)
	C38	Gutniak et al., "Glucagon-Like Insulinotropic Peptide 1 (7-36)--New Approach to Treating Diabetes?," Diabetologia, (Published from the 26.sup.th Annual Meeting of the European Association for the Study of Diabetes), 33(Supp.):A73 (1990)
	C39	Gutniak et al, "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus", *N. Eng. J. Med.*, 326(20):1316-1322 (1992)
	C40	Hargrove et al, "Comparison of the Glucose Dependency of Glucagon-Like Peptide-1(7-37) and Glyburide In Vitro and In Vivo", *Metabolism*, 45(3):404-409 (1996)
	C41	Hargrove et al., "Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37) In Vivo During Short- or Long-Term Administration," *Metabolism*, 44(9):1231-1237 (1995)
	C42	Hendrick et al., "Glucagon-like Peptide 1 (7-37) Blunts Postprandial Glycaemic Excursion in Rats with Mild Diabetes," *Diabetologia*, **Abstract 212**, 32(7):496A (1989)
	C43	Hendrick et al., "Glucagon-like Peptide-I-(7-37) Suppress Hyperglycemia in Rats", *Metabolism*, 42(1):1-6 (1993)
	C44	Hollande et al., "In Vitro Secretion of Gastrin, Insulin, and Glucagon in Tissue Cultures of Pancreas From a Child with Neonatal Intractable Hypoglycemia", *Gastroenterology*, 71:255-262 (1976)
	C45	Holst, J.J., "Glucagon Peptide 1: A Newly Discovered Gastrointestinal Hormone," *Gastroenterology*, 107(6):1848-1855 (1994)
	C46	Holstad et al., "Prolactin Protects Against Diabetes Induced by Multiple Low Doses of Streptozotocin in Mice", *J. Endocrinol.*, 163:229-234 (1999)
	C47	Hui et al., "Glucagon-like peptide 1 induces differentiation of islet duodenalhomeobox-1-positive pancreatic ductal cells into insulin-secreting cells", *Diabetes*, 50:785-796 (2001)
	C48	Hvidberg et al., "Effect of Glucagon-like Peptide-1 (proglucagon78-107amide) on Hepatic Glucose Production in Healthy Man", *Metabolism*, 43(1):104-108 (1994)
	C49	Imura H., "A Novel Antidiabetic Drug, Troglitazone--Reason for Hope and Concern", *N. Engl. J. Med.*, 338:908-909 (1998)
	C50	Iritani et al., "Oral Triacylglycerols Regulate Plasma Glucagon-Like Peptide-1(7-36) and Insulin Levels in Normal and Especially in Obese Rats", *J. Nutr.*, 129:46-50 (1999)
	C51	Johnson et al., "Erythropoietin mimetic peptides and the future", *Nephrol. Dial Tranpl.*, 15:1274-1277 (2000)
	C52	Kaushansky, K., "Hematopoietic growth factor mimetics", *Ann. NY Acad. Sci.*, 938:131-138 (2001)
	C53	Knudsen et al., "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration", *J. Med. Chem.*, 43(9):1664-1669 (2000)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C54	Krakowski et al., "Pancreatic Expression of Keratinocyte Growth Factor Leads to Differentiation of Islet Hepatocytes and Proliferation of Duct Cells", *Am. J. Pathol.*, 154:683-691 (1999)
	C55	Krakowski et al., "Transgenic Expression of Epidermal Growth Factor and Keratinocyte Growth Factor in Beta-Cells Results in Substantial Morphological Changes", *J. Endocrinol.*, 162:167-175 (1999)
	C56	Kreymann et al., "Glucagon-like peptide-1 7-36: A physiological incretin in man," *Lancet*, 2:1300-1304 (1987)
	C57	Kreymann et al., "Glucagon-like Peptide-1 7-36 Amide, A New Brain-Gut Hormone and Its Effect of Pancreatic Endocrine Function in Man," *Biomed. Res.*, 9(Supp. 3):207-211 (1988)
	C58	Kumar, M., "Nano and microparticles as controlled drug delivery devices", *J. Pharm. Pharmaceut. Sci.*, 3:234-258 (2002)
	C59	Kumar et al., "Biodegradable block copolymers", *Adv. Drug Deliv. Rev.*, 53:23-44 (2001)
	C60	Larsen et al., "Glucagons-Like Peptide-1 Infusion Must Be Maintained For 24 H/Day To Obtain Acceptable Glycemia In Type 2 Diabetic Patients Who Are Poorly Controlled On Sulphonylurea Treatment", *Diabetes Care*, 24(8):1416-1421 (2001)
	C61	Larsen et al., "Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats", *Diabetes*, 50:2530-2539 (2001)
	C62	Le Bras et al., "Fibroblast Growth Factor 2 Promotes Pancreatic Epithelial Cell Proliferation Via Functional Fibroblast Growth Factor Receptors During Embryonic Life", *Diabetes* 47:1236-1242 (1998)
	C63	Lima-Leite et al., "Synthesis and Biological Activities of the Human Gastrin analogs", Braz. J. Med. Biol. Res., 29:1253-1263 (1996)
	C64	Lingohr et al., "Activation of IRS-2-Mediated Signal Transduction by IGF-1, but Not TGF- Alpha or EGF, Augments Pancreatic Beta-Cell Proliferation", *Diabetes*, 51:966-976 (2002)
	C65	Logothetopoulos et al., in Handbook of Physiology (Am. Physiol. Soc. Washington, DC), Section 7, Chapter 3, pgs. 67-75 (1972)
	C66	Lu et al., "Keratinocyte growth factor ameliorates streptozotocin-induced, moderate diabetes in rats", *Diabetes*, **Abstract 1030**, 48[s1]:A236 (1999)
	C67	Marchese et al., "Human Keratinocyte Growth Factor Activity on Proliferation and Differentiation of Human Keratinocytes: Differentiation Response Distinguishes KGF From EGF Family", *J. Cell. Physiol.*, 144: 326-332 (1990)
	C68	Morales et al., Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats", *Diabetes*, 46:1264-1269 (1997)
	C69	Movassat et al., "Exendin-4 upregulates expression of PDX-1 and hastens differentiation and maturation of human fetal pancreatic β cells", *Diabetes* , **Abstract 1416-P**, page A341 (2001)
	C70	Nakano et al., "Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts", *Transplantation*, 69(2):214-221 (2000)
	C71	Nathan et al., "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", *Diabetes Care*, 15(2):270-276 (1992)
	C72	Nauck et al., "Preserved Incretin Activity of Glucagon-like Peptide 1 [7-36 Amide] but Not of Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type-2 Diabetes Mellitus," *J. Clin. Invest.*, 91:301-307 (1993)

	C73	Nauck et al., "Additive Insulinopropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1-(7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and glucose Concentrations", *J. Clin. Endo. and Metab.*, 76(4):912-917 (1993)
	C74	Nielsen , J.H., "Effects of Growth Hormone, Prolactin, and Placental Lactogen on Insulin Content and Release, and Deoxyribonucleic Acid Synthesis in Cultured Pancreatic Islets", *Endocrinology*, 110:600-606 (1982)
	C75	Nielsen et al., "The Role of Growth Hormone and Prolactin in Beta Cell Growth and Regeneration", *Adv. Exp. Med. Biol.*, 321:9-17 (1992)
	C76	Ohlsson et al., "The Method of Administration of Cholecystokinin Determines the Effects Evoked in the Pancreas", *Pancreas*, 23:94-101 (2001)
	C77	Ohlsson et al., "The Effect of Intermittent Injections of CCK-8S and the CCK-A Receptor Antagonist Devazepide on Cell Proliferation in Exocrine Rat Pancreas", *Int. J. Pancreatol.*, 24:211-218 (1998)
	C78	Ohlsson et al., "Epidermal growth factor induces cell proliferation in mouse pancreas and salivary glands", *Pancreas*, 14(1):94-98 (1997)
	C79	Parkes et al., "Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 in Vivo and in Vitro", *Metabolism*, 50:583-589 (2001)
	C80	Pederson et al., "Effect of Cholecystokinin, Secretin, and Gastric Inhibitory Polypeptide on Insulin Release From the Isolated Perfused Rat Pancreas", *Can .J. Physiol. Pharmacol.*, 57:1233-1237 (1979)
	C81	Perfetti et al., "Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic- Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats", *Endocrinology*, 141:4600-4605 (2000)
	C82	Pierce et al., "Stimulation of All Epithelial Elements During Skin Regeneration by Keratinocyte Growth Factor", *J. Exp. Med.*, 179:831-840 (1994)
	C83	Proietto et al., "Glucose Utilization in Type 1 (Insulin-Dependent) Diabetes: Evidence for a Defect not Reversible by Acute Elevations of Insulin," *Diabetologia*, 25(4):331-335 (1983)
	C84	Rehfeld et al., T"he Effect of Gastrin on Basal- and Glucose-Stimulated Insulin Secretion in Man", *J. Clin. Invest.*, 52:1415-1426 (1973)
	C85	Rehfeld, J.F., "The New Biology of Gastrointestinal Hormones", *Physiol. Rev.*, 78:1087-1108 (1998)
	C86	Rehfeld et al., "The Effect of Gastrin and Cholecystokinin on the Endocrine Pancreas", *Front. Hormone Res.*, 7:107-118 (1980)
	C87	Ritzel et al., "Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance", *Diabetes*, 50:776-784 (2001)
	C88	Rooman et al., "Effect of Vascular Endothelial Growth Factor on Growth and Differentiation of Pancreatic Ductal Epithelium", *Lab. Invest.*, 76:225-232 (1997)
	C89	Rooman et al., "Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas", *Gastroenterology*, 121:940-949 (2001)
	C90	Rooman et al., "Effects of gastrin on proliferating and differentiation in regenerating pancreas", *Diabetologia*, **Abstract only**, page 106 (2000)
	C91	Rooth et al., "Prevention of detrimental effect of cyclosporine A on vascular ingrowth of transplanted pancreatic islets with verapamil", *Diabetes*, 38(1):202-205 (1989)
	C92	Sasaki et al., "Dietary Docosahexaenoic acid can alter the surface expression of CD4 and CD8 on T cells in peripheral blood", *J. Agric. Food Chem.*, 48(4):1047-1049 (2000)
	C93	Schmidt et al., "Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets," *Diabetologia*, 28:704-707 (1985)
	C94	Shapiro et al., "Combination Therapy With Low Dose Sirolimus and Tacrolimus Is Synergistic in Preventing Spontaneous and Recurrent Autoimmune Diabetes in Non-Obese Diabetic Mice", *Diabetologia*, 45:224-230 (2002)

	C95	Shapiro et al., "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus using a Glucocorticoid-Free Immunosuppressive Regimen", *N. Eng. J. Med.*, 343(4):230-238 (2000)
	C96	Sharma et al., "The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration", *Diabetes*, 48:507-513 (1999)
	C97	SIGMA Big Gastrin 1 human, https://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/G7264
	C98	SIGMA Leu15-Gastrin 1 human, http://www.sigmaaldrich.com/catalog/search/ProductDetail/ProNo=G9145&Brand=Sigma
	C99	Sjoholm et al., 'TGF-Beta Stimulates Insulin Secretion and Blocks Mitogenic Response of Pancreatic Beta-Cells to Glucose", *Am. J. Physiol.*, 260:C1046-C1051 (1991)
	C100	Soon-Shiong et al., "Glucose-Insulin Kinetics of the Extravascular Bioartificial Pancreas", *ASAIO J.*, 38:851-854 (1992)
	C101	Soon-Shiong et al, "Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation" *Lancet*, 343:950-951 (1994)
	C102	Soon-Shiong et al, "Long-term reversal of diabetes by the injection of immunoprotected islets", *Proc. Natl. Acad. Sci. USA*, 90(12):5843-5847 (1993)
	C103	Soon-Shiong et al, "Pancreas and islet-cell transplantation: Potential cure for diabetes", *Transplantation*, 87(8):133-134; 139-140 (1990)
	C104	Soon-Shiong et al., "Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets", *Transplantation*, 54(5):769-774 (1992)
	C105	Staiano-Coico et al., "Human Keratinocyte Growth Factor Effects in a Porcine Model of Epidermal Wound Healing", *J. Exp. Med.*, 178:865-878 (1993)
	C106	Todd et al., "Subcutaneous Glucagon-Like Peptide-1 Improves Postprandial Glycaemic Control Over a 3-Week Period in Patients With Early Type 2 Diabetes", *Clin. Sci.*, 95:325-329 (1998)
	C107	Tourrel et al., "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the Beta-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4", *Diabetes*, 51:1443-1452 (2002)
	C108	Tourrel et al., "Glucagon-Like Peptide-1 and Exendin-4 Stimulate Beta-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age", *Diabetes,* 50:1562-1570 (2001)
	C109	Uttenthal et al., "Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas," *J. Clin. Endocrinol. Metab.*, 61:472-479 (1985)
	C110	Vergelli et al., "Immunosuppresive activity of 13-*cis*-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics", *Immunopharmacology*, 37:191-197 (1997)
	C111	Villanueva-Penacarrillo et al., "Increased Glucagon-like Peptide 1 (7-36) Amide Binding in Adipose Tissue from Non-Insulin Dependent and Insulin-Dependent Diabetic Patients," *Diabetes Nutr. Metab.*, 7(3):143-148 (1994)
	C112	Wang et al., "Intraportal delivery of immunosuppression to intreaheptic islet allograft recipients", *Transpl. Int.*, 8:268-272 (1995)
	C113	Wang et al., "Glucagon-Like Peptide-1 Can Reverse the Age-Related Decline in Glucose Tolerance in Rats", *J. Clin. Invest.*, 99:2883-2889 (1997)
	C114	Wang et al., "Glucagon-Like Peptide-1 Is a Physiological Incretin in Rat", *J. Clin. Invest.*, 95:417-421 (1995)
	C115	Wang et al., "Expression of gastrin and transforming growth factor-α during duct to islet cell differentiation in the pancreas of duct-ligated adult rats", *Diabetologia*, 40:887-893 (1997)
	C116	Wettergren et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," *Digestive Diseases and Sciences*, 38(4):665-673 (1993)

	C117	Winer et al., "Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive", *Nat. Med.*, 9(2):198-205 (2003)
	C118	Wrighton et al., "Small peptides as potent mimetics of the protein hormone erythropoietin", *Science*, 273:458-463 (1996)
	C119	Ye et al., "DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs", *J. Controlled Rel.*, 64:155-166 (2000)
	C120	Young et al., "Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: Studies in Obese Diabetic (Ob/Ob, Db/Db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca Mulatta)", *Diabetes*, 48:1026-1034 (1999)
	C121	Zhou et al., "Glucagon-Like Peptide 1 and Exendin-4 Convert Pancreatic AR42J Cells into Glucagon- and Insulin-Producing Cells", *Diabetes*, 48:2358-2366 (1999)

*** By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A12-A15 and the U.S. Published Applications A16-A26 are not submitted.**

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.